Results of a Prospective Study of High-Dose or Conventional Anthracycline-Cyclophosphamide Regimen Plus Radiotherapy for Localized Adult Non-Hodgkin's Primary Bone Lymphoma

Autor: Jean-Pierre Marolleau, T. Lamy, S Lissandre, B Desablens, Ghandi Damaj, JF Abgrall, Roch Houot, Marie-Pierre Moles-Moreau, Philippe Casassus, Reda Garidi, Aline Schmidt-Tanguy, P Rodon
Přispěvatelé: Jonchère, Laurent, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Service d'hématologie clinique [Avicenne], Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier de Blois (CHB), Laboratoire d'Hématologie [CHU Amiens], CHU Amiens-Picardie, Service clinique des Maladies du Sang, Hôpital Saint-Quentin, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)
Jazyk: angličtina
Rok vydání: 2014
Předmět:
Zdroj: Advances in Hematology
Advances in Hematology, 2014, 2014, pp.512508. ⟨10.1155/2014/512508⟩
Advances in Hematology, Hindawi, 2014, 2014, pp.512508. ⟨10.1155/2014/512508⟩
Advances in Hematology, Vol 2014 (2014)
ISSN: 1687-9104
1687-9112
DOI: 10.1155/2014/512508⟩
Popis: Background. Primary bone lymphoma (PBL) is a rare entity that has only been reviewed in one prospective and small retrospective studies, from which it is difficult to establish treatment guidelines. We prospectively evaluated high-dose or conventional anthracycline-cyclophosphamide dose and radiotherapy for PBL.Patients and Methods. The GOELAMS prospective multicenter study (1986–1998) enrolled adults with localized high-grade PBL according to age and performance status (PS). Patients Results. Among the 26 patients included (VCAP: 19; VCEP-bleomycin: 7), 39% had poor PS ≥2. With a median follow-up of 8 years, overall survival, event-free survival, and relapse-free survival were 64%, 62%, and 65%, respectively, with no significant difference between treatment groups. Poor PS was significantly associated with shorter OS and EFS.Conclusions. Our results confirm the efficacy of our age-based therapeutic strategy. High-doses anthracycline-cyclophosphamide did not improve the outcome. VCEP-bleomycin is effective and well tolerated for old patients. The intensification must be considered for patients with PS ≥2, a poor prognostic factor.
Databáze: OpenAIRE
Externí odkaz: